One pivotal mediator of prostate carcinogenesis is the androgen receptor (AR) pathway. The majority of prostate cancers initially require androgens for growth, and the elimination of testosterone by surgical or chemical castration leads to marked tumor regression through a mechanism of programmed cell death. The manipulation of the androgen-receptor pathway has been used in clinical medicine since the 1940's as the primary treatment of advanced prostate cancer. However, this therapy is palliative and eliminates the potential beneficial effects of androgen-induced cellular differentiation. Surviving cancer cells lose their dependency on androgens over time and are capable of growth in the absence of serum testosterone. The molecular events leading to androgen independence (AI) have not been defined, but potential mechanisms include over expression of the AR, mutations in the AR gene leading to promiscuous ligand binding, and the activation of the AR or downstream regulatory molecules by other growth factors. This proposal will test the hypothesis that specific genes and their cognate proteins downstream of the Androgen Receptor modulate the proliferative, anti-apoptotic, and differentiation effects of the AR in neoplastic prostate epithelial cells. The broad objectives of this proposal are to define these factors, and determine their mechanism(s) of action. This hypothesis will be tested by completing the following specific aims:
Aim 1 : Identify the network of genes directly or indirectly regulated by the Androgen Receptor in the normal and neoplastic human prostate and in mouse models of prostate carcinoma;
Aim 2 : Determine the effects of specific androgen-regulated genes on the programs of prostate differentiation, apoptosis, and proliferation, and to ascertain if augmenting or inhibiting the expression of specific androgen-regulated genes influences the growth of prostate carcinoma cells;
Aim 3 : Determine if specific androgen-regulated genes are involved in mouse prostate development and carcinogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK065204-01
Application #
6683293
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M1))
Program Officer
Margolis, Ronald N
Project Start
2003-08-01
Project End
2007-06-30
Budget Start
2003-08-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$368,920
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Pritchard, Colin C; Nelson, Peter S (2008) Gene expression profiling in the developing prostate. Differentiation 76:624-40
Montgomery, R Bruce; Mostaghel, Elahe A; Vessella, Robert et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-54
Lucas, J M; True, L; Hawley, S et al. (2008) The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 215:118-25
Mostaghel, Elahe A; Page, Stephanie T; Lin, Daniel W et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-41
Xu, Chang; Graf, Lynn F; Fazli, Ladan et al. (2007) Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate 67:1621-9
Bavik, Claes; Coleman, Ilsa; Dean, James P et al. (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66:794-802
Page, Stephanie T; Lin, Daniel W; Mostaghel, Elahe A et al. (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850-6
Marks, Leonard S; Mazer, Norman A; Mostaghel, Elahe et al. (2006) Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351-61
Knudsen, Beatrice (2006) Migrating with myosin VI. Am J Pathol 169:1523-6
Kim, Tom S; Heinlein, Cynthia; Hackman, Robert C et al. (2006) Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 26:965-75

Showing the most recent 10 out of 19 publications